K2 Investment Partners

K2 Investment Partners

K2 Investment Partners was established in 1999 by CEO Park Young-sik, positioning itself as an independent venture capital firm during Korea's emerging VC ecosystem. The firm operated initially under the name KTB Network's predecessor structure before becoming the independent manager recognized today. Its orientation reflects the founder's conviction that Korean technology companies could achieve global scale with the right early-stage backing. The firm invests across early-stage, expansion, and pre-IPO rounds, deploying from both primary and secondary positions. Sector coverage spans enterprise software, industrial technology, digital health, consumer, and fintech. Among the notable exits and portfolio names associated with K2 are Medytox, a biopharmaceutical company that became a major global botulinum toxin producer, and Techwing, a semiconductor test handler manufacturer. The firm has extended its geographic view to support Korean companies expanding into China and Southeast Asian markets. K2 Investment Partners has backed more than 160 portfolio companies since inception. The team operates from Seoul, where it manages multiple venture funds raised from domestic institutional investors. While the firm maintains a low public profile, its longevity places it among the earliest cohort of Korean VC managers that shaped the country's startup financing landscape. A recent operational event includes the firm's continued deployment from its later-stage focused funds, participating in growth rounds for Korean deep-tech companies. K2 Investment Partners operates with a structural profile that is distinct in the Korean market: an independent VC that has sustained over two decades without being absorbed into a larger financial conglomerate. This independence allows the firm to maintain its early-stage thesis while progressively adding later-stage vehicles, creating a full lifecycle investment capability uncommon among boutique Korean managers.